mTOR inhibitors in cancer therapy.

F1000Research

Volumn 5, Issue , 2016, Pages

  Xie, Jianling ^a   Wang, Xuemin ^a,b   Proud, Christopher G ^a,b  

^a SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; AZD 8055; DACTOLISIB; EVEROLIMUS; FULVESTRANT; IBRUTINIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OMIPALISIB; PACLITAXEL; RAPAMYCIN; SAPANISERTIB; SELUMETINIB; TEMSIROLIMUS; VISTUSERTIB; VOXTALISIB;

ADVERSE OUTCOME; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL LINE; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; LUNG CANCER; LYMPHOMA; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

EID: 85010876707     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.9207.1     Document Type: Review

References (82)

1. Kennedy BK, Lamming DW: The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging. Cell Metab. 2016; 23(6): 990-1003.
2. Shimobayashi M, Hall MN: Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014; 15(3): 155-62.
3. Kim YC, Guan KL: mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015; 125(1): 25-32.
4. Jewell JL, Russell RC, Guan KL: Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol. 2013; 14(3): 133-9.
5. Zoncu R, Efeyan A, Sabatini DM: mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011; 12(1): 21-35.
6. Henske EP, Józwiak S, Kingswood JC, et al.: Tuberous sclerosis complex. Nat Rev Dis Primers. 2016; 2: 16035.
7. Brunn GJ, Hudson CC, Sekulic A, et al.: Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science. 1997; 277(5322): 99-101.
8. Siddiqui N, Sonenberg N: Signalling to eIF4E in cancer. Biochem Soc Trans. 2015; 43(5): 763-72.
9. Huo Y, Iadevaia V, Proud CG: Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis. Biochem Soc Trans. 2011; 39(2): 446-50.
10. Iadevaia V, Huo Y, Zhang Z, et al.: Roles of the mammalian target of rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis. Biochem Soc Trans. 2012; 40(1): 168-72.
11. Gaubitz C, Prouteau M, Kusmider B, et al.: TORC2 Structure and Function. Trends Biochem Sci. 2016; 41(6): 532-45.
12. Sarbassov DD, Guertin DA, Ali SM, et al.: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307(5712): 1098-101.
13. Humphrey SJ, Yang G, Yang P, et al.: Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2. Cell Metab. 2013; 17(6): 1009-20.
14. Rosner M, Fuchs C, Siegel N, et al.: Hengstschlager M. Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle. Hum Mol Genet. 2009; 18(17): 3298-310.
15. Yang G, Murashige DS, Humphrey SJ, et al.: A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation. Cell Rep. 2015; 12(6): 937-43.
16. Hers I, Vincent EE, Tavaré JM: Akt signalling in health and disease. Cell Signal. 2011; 23(10): 1515-27.
17. Yuan HX, Guan KL: The SIN1-PH Domain Connects mTORC2 to PI3K. Cancer Discov. 2015; 5(11): 1127-9.
18. Forbes SA, Bindal N, Bamford S, et al.: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011; 39(Database issue): D945-50.
19. Choo AY, Yoon SO, Kim SG, et al.: Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A. 2008; 105(45): 17414-9.
20. Yip CK, Murata K, Walz T, et al.: Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell. 2010; 38(5): 768-74.
21. Aylett CH, Sauer E, Imseng S, et al.: Architecture of human mTOR complex 1. Science. 2016; 351(6268): 48-52.
22. Yuan HX, Guan KL: Structural insights of mTOR complex 1. Cell Res. 2016; 26(3): 267-8.
23. Dowling RJ, Topisirovic I, Alain T, et al.: mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 2010; 328(5982): 1172-6.
24. Chaturvedi D, Gao X, Cohen MS, et al.: Rapamycin induces transactivation of the EGFR and increases cell survival. Oncogene. 2009; 28(9): 1187-96.
25. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, et al.: mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011; 1(3): 248-59.
26. Li J, Kim SG, Blenis J: Rapamycin: one drug, many effects. Cell Metab. 2014; 19(3): 373-9.
27. Liu R, Proud CG: Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases. Acta Pharmacol Sin. 2016; 37(3): 285-94.
28. Thoreen CC, Sabatini DM: Rapamycin inhibits mTORC1, but not completely. Autophagy. 2009; 5(5): 725-6.
29. Sarbassov DD, Ali SM, Sengupta S, et al.: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006; 22(2): 159-68.
30. Julien LA, Carriere A, Moreau J, et al.: mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol. 2010; 30(4): 908-21.
31. Xie J, Proud CG: Signaling crosstalk between the mTOR complexes. Translation (Austin). 2014; 2(1): e28174.
32. Schuler W, Sedrani R, Cottens S, et al.: SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997; 64(1): 36-42.
33. Schuurman HJ, Cottens S, Fuchs S, et al.: SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation. 1997; 64(1): 32-5.
34. Raynaud FI, Eccles SA, Patel S, et al.: Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009; 8(7): 1725-38.
35. Maira S, Stauffer F, Brueggen J, et al.: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008; 7(7): 1851-63.
36. Aziz SA, Jilaveanu LB, Zito C, et al.: Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res. 2010; 16(24): 6029-39.
37. Engelman JA, Chen L, Tan X, et al.: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008; 14(12): 1351-6.
38. Knight SD, Adams ND, Burgess JL, et al.: Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med Chem Lett. 2010; 1(1): 39-43.
39. Yu P, Laird AD, Du X, et al.: Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014; 13(5): 1078-91.
40. Garlich JR, De P, Dey N, et al.: A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008; 68(1): 206-15.
41. Apsel B, Blair JA, Gonzalez B, et al.: Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008; 4(11): 691-9.
42. Feldman ME, Apsel B, Uotila A, et al.: Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009; 7(2): e38.
43. Hsieh AC, Costa M, Zollo O, et al.: Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBPeIF4E. Cancer Cell. 2010; 17(3): 249-61.
44. Hsieh AC, Liu Y, Edlind MP, et al.: The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012; 485(7396): 55-61.
45. Thoreen CC, Kang SA, Chang JW, et al.: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009; 284(12): 8023-32.
46. Liu Q, Xu C, Kirubakaran S, et al.: Characterization of Torin2, an ATPcompetitive inhibitor of mTOR, ATM, and ATR. Cancer Res. 2013; 73(8): 2574-86.
47. García-Martínez JM, Moran J, Clarke RG, et al.: Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J. 2009; 421(1): 29-42.
48. Malagu K, Duggan H, Menear K, et al.: The discovery and optimisation of pyrido[2, 3-d]pyrimidine-2, 4-diamines as potent and selective inhibitors of mTOR kinase. Bioorg Med Chem Lett. 2009; 19(20): 5950-3.
49. Yu K, Toral-Barza L, Shi C, et al.: Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009; 69(15): 6232-40.
50. Chresta CM, Davies BR, Hickson I, et al.: AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010; 70(1): 288-98.
51. Pike KG, Malagu K, Hummersone MG, et al.: Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett. 2013; 23(5): 1212-6.
52. Shapiro AM, Lakey JR, Ryan EA, et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000; 343(4): 230-8.
53. Ryan EA, Paty BW, Senior PA, et al.: Five-year follow-up after clinical islet transplantation. Diabetes. 2005; 54(7): 2060-9.
54. Bell E, Cao X, Moibi JA, et al.: Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes. 2003; 52(11): 2731-9.
55. Zhang N, Su D, Qu S, et al.: Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes. 2006; 55(9): 2429-36.
56. Barlow AD, Xie J, Moore CE, et al.: Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2). Diabetologia. 2012; 55(5): 1355-65.
57. Huang S, Yang ZJ, Yu C, et al.: Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. J Biol Chem. 2011; 286(46): 40002-12.
58. Willems L, Chapuis N, Puissant A, et al.: The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia. 2012; 26(6): 1195-202.
59. Koppenol WH, Bounds PL, Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011; 11(5): 325-37.
60. Alain T, Morita M, Fonseca BD, et al.: eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res. 2012; 72(24): 6468-76.
61. Jacobson BA, Thumma SC, Jay-Dixon J, et al.: Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide. PLoS One. 2013; 8(11): e81669.
62. Moerke NJ, Aktas H, Chen H, et al.: Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell. 2007; 128(2): 257-67.
63. Proud CG: mTORC1 signalling and mRNA translation. Biochem Soc Trans. 2009; 37(Pt 1): 227-31.
64. Romeo Y, Zhang X, Roux PP: Regulation and function of the RSK family of protein kinases. Biochem J. 2012; 441(12): 553-69.
65. Montagne J, Stewart MJ, Stocker H, et al.: Drosophila S6 kinase: a regulator of cell size. Science. 1999; 285(5436): 2126-9.
66. Shima H, Pende M, Chen Y, et al.: Disruption of the p70s6k/p85s6k gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 1998; 17(22): 6649-59.
67. Chauvin C, Koka V, Nouschi A, et al.: Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene. 2014; 33(4): 474-83.
68. Hannan KM, Brandenburger Y, Jenkins A, et al.: mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol. 2003; 23(23): 8862-77.
69. Iadevaia V, Liu R, Proud CG: mTORC1 signaling controls multiple steps in ribosome biogenesis. Semin Cell Dev Biol. 2014; 36: 113-20.
70. Bywater MJ, Poortinga G, Sanij E, et al.: Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell. 2012; 22(1): 51-65.
71. Devlin JR, Hannan KM, Hein N, et al.: Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. Cancer Discov. 2016; 6(1): 59-70.
72. Ghosh AP, Marshall CB, Coric T, et al.: Point mutations of the mTOR-RHEB pathway in renal cell carcinoma. Oncotarget. 2015; 6(20): 17895-910.
73. Grabiner BC, Nardi V, Birsoy K, et al.: A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 2014; 4(5): 554-63.
74. Rodrik-Outmezguine VS, Okaniwa M, Yao Z, et al.: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016; 534(7606): 272-6.
75. Sato T, Nakashima A, Guo L, et al.: Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene. 2010; 29(18): 2746-52.
76. Wagle N, Grabiner BC, van Allen EM, et al.: Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014; 4(5): 546-53.
77. Baker H, Sidorowicz A, Sehgal SN, et al.: Rapamycin (AY-22, 989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo). 1978; 31(6): 539-45.
78. Sehgal SN, Baker H, Vézina C: Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975; 28(10): 727-32.
79. Singh K, Sun S, Vézina C: Rapamycin (AY-22, 989), a new antifungal antibiotic. IV. Mechanism of action. J Antibiot (Tokyo). 1979; 32(6): 630-45.
80. Vézina C, Kudelski A, Sehgal SN: Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975; 28(10): 721-6.
81. Geoerger B, Kerr K, Tang CB, et al.: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 2001; 61(4): 1527-32.
82. Carayol N, Vakana E, Sassano A, et al.: Critical roles for mTORC2-and rapamycininsensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A. 2010; 107(28): 12469-74.